Milo's TA discussion and sharing thread

[chainer9999]

interra burst liao!!!! when tp? can advise?

 

[Sinkie]

anyone wan to provide a counter for moi to jinx it?

Be patient, or tell me a counter, I draw the chart

Over here, we don't put a chart and say its buy or sell or long or short, because we do not want to be seen as trying to attract suckers in to push our existing position like how 688 is doing.

So say a counter, we will give a chart but any counter with likelihood of low or none liquidity like combinewill will not be entertained

Sorry lately abit busy so can't really do a full fledge ta fa pva analysis with caption but just the chart alone

 

[remy3413]

breakout soon?

 

[Bishio]

interra burst liao!!!! when tp? can advise?

wah u keep how long liao. think ard 38-42?

 

[Bishio]

how is noble and dyna mac?

 

[chainer9999]

wah u keep how long liao. think ard 38-42?

39 kekeke

 

[Bishio]

39 kekeke

So patient. Huat big big!

 

[Sinkie]

breakout soon?

Looks good

All eyes tomorrow on that support

 

[ccostagmont]

39 kekeke

gxgx
huat until blc riao...

 

[remy3413]

Looks good

All eyes tomorrow on that support

i think burst liao, GLP reported they leased out in japan

http://info.sgx.com/webcoranncatth.nsf/VwAttachments/Att_E78114EE3BE871FB48257B0100362AFA/$file/01282013_GLP_leases_29K_sqm_to_major_3PL_co.pdf?openelement

 

[chainer9999]

gxgx
huat until blc riao...

i still waiting strike toto rike chiu

 

[Milo-Dino]

your 3rd time in?

ya lor... friday shouldn't have itchy hand go sell...

should have sensed it coming..

 

[Milo-Dino]

breakout soon?

this one i think will breakdown...

just my hunch..

 

[Sinkie]

breakout, can it reach the 135 resistence?

Singapore, 28 January 2013 – Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom™.

BioFreedom represents the latest development in Biosensors’ stent technology, featuring a micro-structured abluminal surface which permits the controlled release of Biolimus A9™ (BA9™) without the use of a polymer. BA9 is a highly lipophilic anti-restenotic drug developed by Biosensors specifically for use with stents.

CE Mark approval for BioFreedom was supported by strong data from the BioFreedom First in Man study. In this study BioFreedom was compared to Boston Scientific’s Taxus™ Liberté™ drug-eluting stent (DES). At 12 months, BioFreedom demonstrated equivalent efficacy, measured by in-stent late lumen loss, compared with Taxus Liberté, with a trend towards superiority. Median in-stent late lumen loss in patients receiving BioFreedom was reduced to 0.17 mm as compared with a median in-stent late lumen loss of 0.35 mm in the Taxus Liberté group. Three year clinical results, presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in October 2012, showed similar rates of MACE (Major Adverse Cardiac Events) between BioFreedom and Taxus Liberté, with no evidence of stent thrombosis in either group.

To further evaluate BioFreedom in a larger patient population, Biosensors recently announced initiation of enrolment in LEADERS FREE, the world’s first prospective, randomised double-blind trial between a DCS and bare-metal stent (BMS), exclusively involving patients at high risk of bleeding. The study has been designed to confirm that BioFreedom is as safe as a BMS in this patient group, and can deliver the anti-restenotic benefit of a DES, with only a one-month course of dual anti-platelet therapy administered to all patients.

 

[Sinkie]

research reports
1) Biosensors Int'l cimb -> 8 nov 2012

Spoiler

Biosensors’ share price has taken a beating from earnings worries following news of Terumo’s weak licensing fee to BIG. Management shrugged it off as a 2Q blip and reiterated its strong revenue guidance. 2Q/1HFY13 core net profit was broadly in line, at 23%/46% of our full-year forecasts and 20%/39% of consensus numbers. Nevertheless, we cut FY3/13 earnings and our SOP target price to reflect the risk of weaker licensing income from Japan and potential price cuts in various countries. This does not affect our Outperform call as product profitability remains strong and valuations are really palatable now.

- 7/2/2013 announcing earnings
- daily shares buyback from management

Singapore, 28 January 2013 – Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom™.

BioFreedom represents the latest development in Biosensors’ stent technology, featuring a micro-structured abluminal surface which permits the controlled release of Biolimus A9™ (BA9™) without the use of a polymer. BA9 is a highly lipophilic anti-restenotic drug developed by Biosensors specifically for use with stents.

CE Mark approval for BioFreedom was supported by strong data from the BioFreedom First in Man study. In this study BioFreedom was compared to Boston Scientific’s Taxus™ Liberté™ drug-eluting stent (DES). At 12 months, BioFreedom demonstrated equivalent efficacy, measured by in-stent late lumen loss, compared with Taxus Liberté, with a trend towards superiority. Median in-stent late lumen loss in patients receiving BioFreedom was reduced to 0.17 mm as compared with a median in-stent late lumen loss of 0.35 mm in the Taxus Liberté group. Three year clinical results, presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in October 2012, showed similar rates of MACE (Major Adverse Cardiac Events) between BioFreedom and Taxus Liberté, with no evidence of stent thrombosis in either group.

To further evaluate BioFreedom in a larger patient population, Biosensors recently announced initiation of enrolment in LEADERS FREE, the world’s first prospective, randomised double-blind trial between a DCS and bare-metal stent (BMS), exclusively involving patients at high risk of bleeding. The study has been designed to confirm that BioFreedom is as safe as a BMS in this patient group, and can deliver the anti-restenotic benefit of a DES, with only a one-month course of dual anti-platelet therapy administered to all patients.

1.35 target met

 

[ccostagmont]

must see news.

ta ma de
srsly, wat ish dis company doing ah?
i see ish boleh land ones?

bo tai bo ji can chiong +17% today?

i went to their webby ssrr, onri haf one smlj pg comms biz unit.

totally baffling...

 

[remy3413]

1.35 target met

Next resistance at 1.46?

I took a position in GLP this morning, the support seems strong

 

[Sinkie]

Next resistance at 1.46?

I took a position in GLP this morning, the support seems strong

news out, but no movement, abit worrying

i think i queue 260 better.. but well glp 271 as we speaks.. maybe news travel slow

or else probably i will go 273

 

[Sinkie]

next resistence soon

cwt

 

[remy3413]

news out, but no movement, abit worrying

i think i queue 260 better.. but well glp 271 as we speaks.. maybe news travel slow

or else probably i will go 273

My filled order was done by a BB though, but I see the 2.68 2.69 levels through market depth, quite hard to break through

Did you take a position in biosensors?